Biotechnology
Global Cord Blood Corporation Appoints Mr. Siu Chuen Cheng as Independent Non-executive Director
HONG KONG, Feb. 6, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of Mr.Siu Chuen Chen...
2020-02-06 19:30
7064
Global Cord Blood Corporation Appoints Mr. Siu Chuen Cheng as Independent Non-executive Director
HONG KONG, Feb. 6, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of Mr.Siu Chuen Chen...
2020-02-06 19:30
12680
French Biotech TargEDys® Announces Positive Results of Its Clinical Trial With Its Probiotic Strain Hafnia alvei HA4597™ on the Weight Loss Thanks to Regulation of Appetite
PARIS, Feb. 6, 2020 /PRNewswire/ -- TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multicentric clinical study carried out on 229 subjects and evaluating the efficacy ofHafnia alvei HA4597™ in the weight loss by regulation of the appe...
2020-02-06 09:07
2374
Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer
MUMBAI, India, Feb. 6, 2020 /PRNewswire/ -- A new study
2020-02-06 08:00
2372
Bridge Biotherapeutics Acquires a New Drug Development Candidate for Back-Eye Diseases
* Signed a collaboration and license agreement for developing back-eye disease treatments with Konkuk University in the Republic of Korea * A total of 10B KRW deal includes 300M KRW of upfront payment SEONGNAM, South Korea, Feb. 5, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical ...
2020-02-05 13:21
1154
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
PLYMOUTH MEETING, Pennsylvania, Feb. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory pap...
2020-02-03 21:00
2440
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
- Belantamab mafodotin accepted for accelerated assessment by the EMA's Committee for Human Medicinal Products (CHMP) - Submission based on data from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) recently published inThe Lancet Oncology LONDON, Feb. 3,...
2020-02-03 17:00
9186
Oxford Nanopore Sequencers Have Left UK for China, to Support Rapid, Near-sample Coronavirus Sequencing for Outbreak Surveillance
OXFORD, England, Feb. 3, 2020 /PRNewswire/ -- Following extensive support of, and collaboration with, public health professionals inChina, Oxford Nanopore has shipped an additional 200 MinION sequencers and related consumables toChina . These will be used to support the ongoing surveillance of the...
2020-02-03 05:20
2654
Coronavirus: New Gear Offers Protection For Patients And Healthcare Workers
MIAMI, Jan. 31, 2020 /PRNewswire/ -- In the ongoing war against Coronavirus, a new technology can provide much-needed protection and benefits for patients and healthcare workers.Radiation Shield Technologies' Demron Chemical Biological Radiological and Nuclear suits have patented thermal conducti...
2020-01-31 07:02
2222
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
Agreement will facilitate clinical trial translations in China PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development inChina of INO-4800, Inovio'...
2020-01-30 19:00
4226
Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio
CAMBRIDGE, England and MILPITAS, Calif., Jan. 30, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science res...
2020-01-30 15:00
1178
MiRXES collaborates with NUS and DxD Hub to move Singapore to the forefront of global microRNA research and application
SINGAPORE, Jan. 29, 2020 /PRNewswire/ -- MiRXES, a leading Singaporean biotech start-up in microRNA[1] (miRNA) technology and diagnostics, collaborated with NUS and DxD Hub to mark the tenth year of miRNA research and clinical translation inSingapore. These organizations jointly led a non-coding ...
2020-01-29 10:00
2069
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
SHANGHAI, Jan. 29, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has stepped up its efforts in enabling the development of multipl...
2020-01-29 10:00
3323
Sales of Cordyceps Mycelia Products Surged over 100% in January
NANPING, China, Jan. 28, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the sales of its Cordyceps mycelia products surged over 100% in January due to the outbreak ...
2020-01-28 22:09
8995
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient inAustralia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an...
2020-01-24 14:26
3511
CyberMDX Research Team Discovers Collection of GE Medical Device Vulnerabilities -- "MDhex"
CISA ICS has Issued an Advisory Containing 6 High-Severity CVEs for GE CARESCAPE, ApexPro, and Clinical Information Center (CIC) systems NEW YORK, Jan. 24, 2020 /PRNewswire/ -- A collection of six cybersecurity vulnerabilities has been discovered in a range of GE Healthcare devices popular ...
2020-01-24 02:48
1294
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...
2020-01-24 00:26
4000
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients inChina from China's National Medical Products Administration. ASC22 is a first-in-class, subcuta...
2020-01-23 09:52
3166
Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
MEMPHIS, Tennessee, Jan. 21, 2020 /PRNewswire/ -- Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products today announced that it has completed the acquisition of Cobra Biologics, a leading CDMO speciali...
2020-01-22 08:04
2912
Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody
SUZHOU and HANGZHOU, China, Jan. 20, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D and manufacturing of antibody-based therapeutics, announces today that an investigational new drug (IND) appl...
2020-01-21 00:00
914
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
